Show simple item record

dc.contributor.authorMizrahi, JD
dc.contributor.authorSurana, R
dc.contributor.authorValle, Juan W
dc.contributor.authorShroff, RT
dc.date.accessioned2020-08-10T08:09:22Z
dc.date.available2020-08-10T08:09:22Z
dc.date.issued2020en
dc.identifier.citationMizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020;395(10242):2008-20.en
dc.identifier.pmid32593337en
dc.identifier.doi10.1016/s0140-6736(20)30974-0en
dc.identifier.urihttp://hdl.handle.net/10541/623105
dc.description.abstractPancreatic cancer is a highly fatal disease with a 5-year survival rate of approximately 10% in the USA, and it is becoming an increasingly common cause of cancer mortality. Risk factors for developing pancreatic cancer include family history, obesity, type 2 diabetes, and tobacco use. Patients typically present with advanced disease due to lack of or vague symptoms when the cancer is still localised. High quality computed tomography with intravenous contrast using a dual phase pancreatic protocol is typically the best method to detect a pancreatic tumour and to determine surgical resectability. Endoscopic ultrasound is an increasingly used complementary staging modality which also allows for diagnostic confirmation when combined with fine needle aspiration. Patients with pancreatic cancer are often divided into one of four categories based on extent of disease: resectable, borderline resectable, locally advanced, and metastatic; patient condition is also an important consideration. Surgical resection represents the only chance for cure, and advancements in adjuvant chemotherapy have improved long-term outcomes in these patients. Systemic chemotherapy combinations including FOLFIRINOX (5-fluorouracil, folinic acid [leucovorin], irinotecan, and oxaliplatin) and gemcitabine plus nab-paclitaxel remain the mainstay of treatment for patients with advanced disease. Data on the benefit of PARP inhibition as maintenance therapy in patients with germline BRCA1 or BRACA2 mutations might prove to be a harbinger of advancement in targeted therapy. Additional research efforts are focusing on modulating the pancreatic tumour microenvironment to enhance the efficacy of the immunotherapeutic strategies.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/s0140-6736(20)30974-0en
dc.titlePancreatic canceren
dc.typeArticleen
dc.contributor.departmentDivision of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.en
dc.identifier.journalLanceten
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record